Meeting
2021 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients.
Presenter
Mario E. Lacouture, MD
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT04088318
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS12132)
DOI
10.1200/JCO.2021.39.15_suppl.TPS12132
Abstract #
TPS12132
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.
Speaker: Sawsan Rashdan, MD
Videos & Slides
2024 ASCO Annual Meeting
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
Speaker: Vanesa Gregorc, MD
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.
Speaker: Jihong Liu
Videos & Slides
2024 ASCO Annual Meeting
BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.
Speaker: Wutong Ju